https://wikimd.org/index.php?action=history&feed=atom&title=NafithromycinNafithromycin - Revision history2026-04-26T10:06:21ZRevision history for this page on the wikiMediaWiki 1.44.2https://wikimd.org/index.php?title=Nafithromycin&diff=6427746&oldid=prevPrab: CSV import2025-03-05T06:12:56Z<p>CSV import</p>
<p><b>New page</b></p><div>{{Short description|A macrolide antibiotic}}<br />
{{Drugbox<br />
| verifiedfields = changed<br />
| verifiedrevid = 477002123<br />
| image = [[File:Nafithromycin_structure.png|thumb|Chemical structure of Nafithromycin]]<br />
| image2 = <br />
| tradename = <br />
| synonyms = <br />
| legal_status = <br />
| routes_of_administration = <br />
| bioavailability = <br />
| protein_bound = <br />
| metabolism = <br />
| elimination_half-life = <br />
| excretion = <br />
| CAS_number = <br />
| ATC_prefix = <br />
| ATC_suffix = <br />
| PubChem = <br />
| DrugBank = <br />
| ChemSpiderID = <br />
| UNII = <br />
| KEGG = <br />
| ChEBI = <br />
| ChEMBL = <br />
| IUPAC_name = <br />
| C= <br />
| H= <br />
| N= <br />
| O= <br />
| molecular_weight = <br />
}}<br />
<br />
'''Nafithromycin''' is a novel [[macrolide]] antibiotic that is being developed for the treatment of [[bacterial infections]]. It belongs to the class of antibiotics known as [[ketolides]], which are derived from macrolides and are designed to overcome certain types of bacterial resistance.<br />
<br />
==Mechanism of Action==<br />
Nafithromycin works by inhibiting bacterial [[protein synthesis]]. It binds to the 50S subunit of the bacterial [[ribosome]], thereby interfering with the translocation step in protein synthesis. This action prevents the growth and replication of bacteria, making it effective against a variety of [[Gram-positive bacteria]].<br />
<br />
==Clinical Uses==<br />
Nafithromycin is primarily being investigated for its use in treating [[community-acquired pneumonia]] and other respiratory tract infections. Its efficacy against [[macrolide-resistant]] strains of bacteria makes it a promising candidate for treating infections that are difficult to manage with existing antibiotics.<br />
<br />
==Pharmacokinetics==<br />
The pharmacokinetic profile of Nafithromycin includes its absorption, distribution, metabolism, and excretion. It is designed to have a favorable bioavailability when administered orally, and it is metabolized in the liver. The elimination half-life allows for convenient dosing schedules, which can improve patient compliance.<br />
<br />
==Development and Research==<br />
Nafithromycin is currently undergoing clinical trials to evaluate its safety and efficacy. Research is focused on its potential to treat infections caused by resistant strains of bacteria, which is a growing concern in the field of [[infectious diseases]].<br />
<br />
==Related Pages==<br />
* [[Macrolide antibiotics]]<br />
* [[Antibiotic resistance]]<br />
* [[Community-acquired pneumonia]]<br />
<br />
[[Category:Macrolide antibiotics]]<br />
[[Category:Antibacterial drugs]]<br />
[[Category:Experimental drugs]]</div>Prab